Clinical trials: Cancer of Thorax
Fungal Diseases, Lung Cancer (NSCLC)
Study on the Microbial Environment of Non-small Cell Lung Cancer Based on Mycogenomics and Its Clinical Relevance
This study aims to uncover the characteristics of the fungal flora in non-small cell lung cancer, and to investigate the relationship between pulmonary fungi and the various pathological subtypes, stages, clinical features of…
- Conditions
- Fungal Diseases, Lung Cancer (NSCLC), Microbioata
- Trial name
- NCT07783971
- Where
- China
- Volunteers
- 10 people
- Sponsor
- 958th Army Hospital of the Chinese People's Liberation Army
NSCLC, Stage I
Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
This is a prospective, open, single-center, single-arm phase II clinical study with common EGFR-sensitive mutations (Ex19del and L858R) identified in the central laboratory.To evaluate the efficacy and safety of adjuvant…
- Trial name
- NCT05686434
- Testing
- Osimertinib
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Epithelial Mesothelioma, Recurrent Malignant Mesothelioma
Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
This phase II trial is studying how well sorafenib works in treating patients with malignant mesothelioma. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood…
- Conditions
- Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma, Stage IA Malignant Mesothelioma
- Trial name
- NCT00107432
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer)
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
This is a Phase Ib/II clinical study. The Phase Ib dose-escalation study aims to evaluate and determine the recommended Phase II dose (RP2D) of TCC1727 in combination with benmelstobart /olaparib /topotecanfor patients with…
- Conditions
- Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer
- Trial name
- NCT07371663
- Testing
- TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg
- Where
- 3 sites in China
- Volunteers
- 266 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Stage IIIA Non-small Cell Lung Cancer
Pathological Response After Neoadjuvant Treatment on NSCLC
This is a non-interventional, observational, multicenter and retrospective study. Being limited to the collection of patient data already filled in the Tumor Thoracic Registry data base and the data from stage IIIA clinical…
- Trial name
- PLANET (NCT05167487)
- Testing
- Cisplatin, Carboplatin
- Where
- 17 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Fundación GECP
Malignancy
Does Transcranial Magnetic Stimulation of the Cingulate Cortex Modulate the Perception of Dyspnoea?
The treatment we are studying is Transcranial Magnetic Stimulation (TMS). In TMS, an electromagnetic pulse is passed into the brain through a coil placed on the head.
- Trial name
- TMS (NCT00830921)
- Testing
- Transcranial Magnetic Stimulation
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University of Oxford
Gastro-intestinal Cancer, Lung Cancer
The Impact of a Patient Education Intervention for Ambulatory Oncology Patients
This study will test the impact of newly created and available symptom management patient education brochures on symptom burden [measured via the Edmonton Symptom Assessment System (ESAS)], health-related quality of life…
- Conditions
- Gastro-intestinal Cancer, Lung Cancer, Head and Neck Cancer, Breast Cancer
- Trial name
- NCT02038114
- Testing
- Instructed to read patient education pamphlets
- Where
- Canada
- Volunteers
- 96 people
- Sponsor
- Sunnybrook Health Sciences Centre
Non-small-cell Lung Cancer
Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients
The purpose of this study is to evaluate the overall response rate and disease free survival for IIIAN2 non-small-cell lung cancer patients with EGFR 19 or 21 exon mutation.
- Trial name
- NCT01843647
- Testing
- Icotinib, Chemotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Non-Small Cell Carcinoma of Lung
Aspects of Quality of Life During Adjuvant Oncological Treatment for Locally Advanced Lung Cancer Which Include Immune Checkpoint Inhibitor.
Current oncological treatment for patients with locally advanced lung cancer comprise adjuvant immunotherapy (immune checkpoint inhibitors-ICI) as an additional one-year treatment after chemoradiotherapy which increases overall…
- Trial name
- NCT07754409
- Where
- Sweden
- Volunteers
- 75 people
- Sponsor
- Göteborg University
Recurrent Small Cell Lung Cancer
CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
This pilot clinical trial studies CPI-613 (6,8-bis[benzylthio]octanoic acid) in treating patients with relapsed or refractory small cell lung cancer.
- Trial name
- NCT01931787
- Testing
- 6,8-bis(benzylthio)octanoic acid
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Wake Forest University Health Sciences
Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma
Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer
This phase Ib trial tests the side effects and best dose of minnelide when given together with osimertinib for the treatment of non-small cell lung cancer that has spread to other places in the body (advanced) and has a change…
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT05166616
- Testing
- Biopsy, Osimertinib, Triptolide Analog
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- City of Hope Medical Center
Non Small Cell Lung Cancer, Advanced Solid Tumor
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
A phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TGRX-1942 in patients with advanced solid tumor and/or relapsed or refractory hematological malignancies
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Hematologic Malignancy
- Trial name
- NCT06484816
- Testing
- TGRX-1942
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Carcinoma, Non-Small-Cell Lung
A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)
Evaluation of gemcitabine and cisplatin in combination with either sorafenib or placebo for the treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC)
- Trial name
- NEXUS (NCT00449033)
- Testing
- Sorafenib (Nexavar, BAY43-9006), Gemcitabine, Cisplatin
- Where
- 122 sites in Austria, Belgium and 16 more
- Volunteers
- 904 people
- Sponsor
- Bayer
Non-small Cell Lung Cancer
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
This study will compare overall survival in participants with Stage IIIB or IV nonsquamous non-small cell lung cancer.
- Trial name
- NCT00762034
- Testing
- Pemetrexed, Paclitaxel, Carboplatin
- Where
- 67 sites in United States
- Volunteers
- 939 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer, Quality of Life
LIFE - Lung Cancer, Immunotherapy, Frailty, Effect
The LIFE study (Lung cancer, Immunotherapy, Frailty, Effect) is investigating the unselected 'real life' non-small cell lung cancer (NSCLC) population treated with immune checkpoint inhibition.
- Conditions
- Non-small Cell Lung Cancer, Quality of Life, Brain Metastases, Venous Thromboembolism
- Trial name
- NCT03870464
- Testing
- CT-scans extended, MRI scan of the brain, Prospective registration of irAEs
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- University of Southern Denmark
Neoplasms, Neoplasms, Glandular and Epithelial
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
The objectives of this study are to explore different dosing levels and schedules of entinostat in combination with pembrolizumab in patients with advanced solid tumors, in terms of safety, tolerability, pharmacokinetics (PK)…
- Conditions
- Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms
- Trial name
- NCT02909452
- Testing
- Entinostat, Pembrolizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Syndax Pharmaceuticals
Non-small Cell Lung Cancer
A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets
This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) of single and multiple oral doses of TQ-A3334 and observe the efficacy of TQ-A3334 in combination with anlotinib capsules…
- Trial name
- NCT04273815
- Testing
- TQ-A3334, Anlotinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer, Metastatic Breast Cancer
Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases
This study is to find an optimal dose of Imiquimod (IMQ) in the first part (Phase I) and test the effectiveness of the combination treatment of IMQ, cyclophosphamide (CTX), and radiotherapy (RT) in patients with skin metastases…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01421017
- Testing
- Radiation, Imiquimod, Cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- NYU Langone Health
Indeterminate Pulmonary Nodules, Lung Metastases
AI & Radiomics for Stratification of Lung Nodules After Radically Treated Cancer
This study will assess the utility of radiomics and artificial intelligence approaches to new lung nodules in patients who have undergone radical treatment for a previous cancer.
- Conditions
- Indeterminate Pulmonary Nodules, Lung Metastases, Second Primary Cancer, Lung Cancer
- Trial name
- AI-SONAR (NCT05375591)
- Testing
- Non-Interventional Study
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Lung Cancer, Metastatic Cancer
Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00738335
- Testing
- erlotinib hydrochloride, immunoenzyme technique, laboratory biomarker analysis
- Where
- United States
- Sponsor
- University of California, San Francisco